Gibson Christopher 4

What Happened
Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), converted Class B common shares into Class A shares and sold 40,000 shares in an open-market transaction on April 7, 2026. The shares were sold at $3.10 each for total proceeds of $124,000. The conversion is recorded at $0 per share (a conversion of convertible Class B into Class A).

Key Details

• Transaction date: 2026-04-07. Sale price: $3.10 per share; proceeds $124,000. Conversion price shown as $0 (conversion of Class B to Class A).
• Report filed: 2026-04-08 (timely filing).
• Transaction codes: C = conversion of a derivative/convertible security; S = sale (open market).
• Notable footnotes: F1 — Class B shares are convertible into Class A at holder’s option with no expiration; F2 — the sale was made pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025. Other footnotes list holdings in family/LLC entities and option vesting schedules.
• Shares owned after the transaction are not specified in the provided filing excerpt.

Context
The filing shows a conversion of convertible (Class B) shares into Class A common stock and an immediate open‑market sale of those shares under a pre-established 10b5‑1 plan. Conversions at $0 reflect a change in share class rather than a paid option exercise. Sales under 10b5‑1 plans are typically prearranged and do not by themselves indicate the insider’s current view on the company.